📊 MBRX Key Takeaways
Is MBRX a Good Investment? Thesis Analysis
Moleculin Biotech is a pre-revenue pharmaceutical company burning through cash with no commercially viable products generating revenue. The company is operating at significant losses with negative cash flow of $22.7M annually, while cash reserves of $8.9M provide only 4-5 months of runway at current burn rates, creating critical liquidity concerns.
Why Buy MBRX? Key Strengths
- Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk
- Adequate current ratio of 1.41x suggesting near-term liquidity coverage for current liabilities
- Low capital expenditure requirements ($0M) allowing cash preservation for operations
MBRX Investment Risks to Consider
- Critical burn rate of $22.7M annually with only ~5 months of cash runway remaining
- Zero revenue generation indicates no commercialized products or viable business model
- Severely negative returns (ROE -223.6%, ROA -151.7%) demonstrating value destruction
- Continued massive operating losses ($25.1M) with negative net income of $33.6M unsustainable
- No insider buying activity in last 90 days suggests lack of confidence from management
Key Metrics to Watch
- Cash balance depletion rate and timeline to cash runway exhaustion
- Revenue generation milestones from clinical trials or product commercialization
- Monthly operating burn rate and any evidence of cost reduction initiatives
- Funding announcements or capital raises to extend runway
- Clinical trial progress and regulatory approval status for pipeline candidates
MBRX Financial Metrics
💡 AI Analyst Insight
Moleculin Biotech, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
MBRX Profitability Ratios
MBRX vs Healthcare Sector
How Moleculin Biotech, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MBRX Overvalued or Undervalued?
Based on fundamental analysis, Moleculin Biotech, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MBRX Balance Sheet & Liquidity
MBRX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Moleculin Biotech, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-189.14 indicates the company is currently unprofitable.
MBRX Growth Metrics (YoY)
MBRX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.9M | $-0.63 |
| Q2 2025 | N/A | -$4.3M | $-0.49 |
| Q1 2025 | N/A | -$5.0M | $-0.69 |
| Q3 2024 | N/A | -$4.3M | $-2.82 |
| Q2 2024 | N/A | -$4.3M | $-1.70 |
| Q1 2024 | N/A | -$5.0M | $-2.02 |
| Q3 2023 | N/A | -$5.6M | $-0.19 |
| Q2 2023 | N/A | -$6.0M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MBRX Capital Allocation
MBRX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Moleculin Biotech, Inc. (CIK: 0001659617)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBRX
What is the AI rating for MBRX?
Moleculin Biotech, Inc. (MBRX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBRX's key strengths?
Claude: Minimal debt burden with 0.00x debt-to-equity ratio reducing financial leverage risk. Adequate current ratio of 1.41x suggesting near-term liquidity coverage for current liabilities.
What are the risks of investing in MBRX?
Claude: Critical burn rate of $22.7M annually with only ~5 months of cash runway remaining. Zero revenue generation indicates no commercialized products or viable business model.
What is MBRX's revenue and growth?
Moleculin Biotech, Inc. reported revenue of $0.0.
Does MBRX pay dividends?
Moleculin Biotech, Inc. does not currently pay dividends.
Where can I find MBRX SEC filings?
Official SEC filings for Moleculin Biotech, Inc. (CIK: 0001659617) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBRX's EPS?
Moleculin Biotech, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Moleculin Biotech, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBRX stock overvalued or undervalued?
Valuation metrics for MBRX: ROE of -223.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBRX stock in 2026?
Our dual AI analysis gives Moleculin Biotech, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBRX's free cash flow?
Moleculin Biotech, Inc.'s operating cash flow is $-22.7M, with capital expenditures of $0.0.
How does MBRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -223.6% (avg: 15%), current ratio 1.41 (avg: 2).